13-valent pneumococcal conjugate vaccine + trivalent inactivated influenza vaccine

This is a combination of two vaccines administered together: - The **13-valent pneumococcal conjugate vaccine (PCV13)**, commonly known as Prevnar 13, is designed to provide active immunization against pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes included in the formulation. It works by inducing an immune response to the polysaccharide antigens of these serotypes conjugated to a carrier protein. - The **trivalent inactivated influenza vaccine (TIV)** is formulated annually to protect against three strains of seasonal influenza virus (typically two A subtypes and one B subtype). It contains inactivated viral antigens that stimulate protective antibody responses. The combination has been studied for coadministration primarily in adults aged 50 years or older. Clinical trials have shown that simultaneous administration is generally well tolerated but may result in slightly lower antibody responses for some pneumococcal serotypes compared with separate administration; the clinical significance of this reduction remains uncertain. Both components are approved individually for prevention of their respective diseases[2][3][6].

Brand names

Prevnar 13 + various TIV brands

Other names

PCV13 + TIV13-valent pneumococcal conjugate vaccine + trivalent inactivated influenza vaccinePCV13 plus TIVPCV-13 plus TIVPCV 13 plus TIVPrevnar 13 plus trivalent influenza vaccinePrevnar13 plus trivalent influenza vaccinePrevnar-13 plus trivalent influenza vaccine